.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Teva
Cerilliant
Fish and Richardson
Novartis
Healthtrust
Deloitte
Argus Health
McKinsey
Moodys

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,344,212

« Back to Dashboard

Summary for Patent: 6,344,212

Title: Method of providing sustained analgesia with buprenorphine
Abstract:A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
Inventor(s): Reder; Robert F. (Greenwich, CT), Kaiko; Robert F. (Weston, CT), Goldenheim; Paul D. (Wilton, CT)
Assignee: Euro-Celtique S.A. (Luxembourg, LU)
Application Number:09/756,419
Patent Claim Types:
see list of patent claims
Use; Delivery;

No matches for this query

International Patent Family for Patent: 6,344,212

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria336212► Subscribe
Austria538765► Subscribe
Austria556682► Subscribe
Australia2004218685► Subscribe
Australia2008261134► Subscribe
Australia2012244363► Subscribe
Australia2013204227► Subscribe
Australia2925402► Subscribe
Australia6184198► Subscribe
Australia743071► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Deloitte
Baxter
Medtronic
Teva
Daiichi Sankyo
Federal Trade Commission
Merck
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot